Pfizer (NYSE: PFE) CEO Bourla granted cash-settled phantom stock units

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

BOURLA ALBERT reported acquisition or exercise transactions in this Form 4 filing.

Pfizer Inc. Chairman & CEO Albert Bourla received a grant of 23 phantom stock units tied to Pfizer common stock at a reference price of $26.00 per unit. This award increases his phantom stock unit balance to 772,772 units, which are cash-settled after his separation from service.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider BOURLA ALBERT

Role Chairman & CEO

Type	Security	Shares	Price	Value
Grant/Award	Phantom Stock Units SSP	23	$26.00	$598.00

Holdings After Transaction: Phantom Stock Units SSP — 772,772 shares (Direct, null)

Footnotes (1)

Each unit represents one phantom share of common stock. These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time.

Key Figures

Phantom stock units granted: 23 units Reference price per unit: $26.00 per unit Total phantom units after grant: 772,772 units +1 more

4 metrics

Phantom stock units granted 23 units Grant of phantom stock units on 2026-06-15

Reference price per unit $26.00 per unit Accounting price for newly granted phantom units

Total phantom units after grant 772,772 units Phantom stock units held following this transaction

Underlying security shares 23 shares equivalent Each phantom unit represents one phantom share of common stock

Key Terms

Phantom Stock Units SSP, Nonfunded Deferred Compensation and Supplemental Savings Plan, phantom share of common stock, settled in cash, +1 more

5 terms

Phantom Stock Units SSP financial

"security_title: "Phantom Stock Units SSP""

Nonfunded Deferred Compensation and Supplemental Savings Plan financial

"acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan"

settled in cash financial

"are settled in cash following the reporting person's separation from service"

alternative investment account financial

"may be transferred by the reporting person into an alternative investment account at any time"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

06/16/2026 - 04:21 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BOURLA ALBERT

(Last)

(First)

(Middle)

66 HUDSON BOULEVARD EAST

ATTN: CORPORATE SECRETARY

(Street)

NEW YORK

10001-2192

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
PFIZER INC [ PFE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chairman & CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Phantom Stock Units SSP	⁽¹⁾	06/15/2026		A		23		⁽²⁾	⁽²⁾	Common Stock	23	$26	772,772	D

Explanation of Responses:

1. Each unit represents one phantom share of common stock.

2. These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time.

	/s/ Shanice A. Reid, by power of atty., for Albert Bourla	06/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Pfizer (PFE) CEO Albert Bourla report in this Form 4 filing?

Albert Bourla reported receiving 23 phantom stock units linked to Pfizer common stock at a reference price of $26.00 per unit. These units are part of his deferred compensation and increase his total phantom stock balance to 772,772 units.

What are the phantom stock units received by Pfizer (PFE) CEO Albert Bourla?

The phantom stock units are deferred compensation instruments, each representing one phantom share of Pfizer common stock. They track the value of the stock but are settled in cash, not actual shares, pursuant to Pfizer’s Nonfunded Deferred Compensation and Supplemental Savings Plan.

How many phantom stock units does Pfizer (PFE) CEO Albert Bourla hold after this transaction?

After this grant of 23 units, Albert Bourla holds 772,772 phantom stock units. This figure reflects his accumulated balance under Pfizer’s Nonfunded Deferred Compensation and Supplemental Savings Plan, all of which are designed to be settled in cash upon separation from service.

At what price were Albert Bourla’s new Pfizer (PFE) phantom stock units granted?

The 23 newly granted phantom stock units were recorded at a reference price of $26.00 per unit. This price is used for the award’s accounting and tracking under the plan, rather than representing an open-market purchase or sale of Pfizer common shares.

How and when are Pfizer (PFE) phantom stock units for Albert Bourla settled?

The phantom stock units are settled in cash following Albert Bourla’s separation from service with Pfizer. Under the company’s Nonfunded Deferred Compensation and Supplemental Savings Plan, these units may also be transferred into an alternative investment account at any time before settlement.

Do Albert Bourla’s Pfizer (PFE) phantom stock units give him actual shares or voting rights?

The phantom stock units do not represent actual Pfizer shares and are settled only in cash. They mirror the value of Pfizer common stock but do not directly provide share ownership or voting rights, functioning instead as a deferred cash-based compensation vehicle.